Balance Sheet

Accounts Payables Accumulated Expenses Assets Buildings Cash & Current Investments Cash & Equivalents Common Equity Curent Deferred Tax Liability Current Assets Current Deferred Revenue Current Deferred Tax Assets Current Leases Current Taxes Finished Goods Goodwill Goodwill & Intangibles Intangibles Inventory Land & Improvements Liabilities and Shareholders Equity Long-Term Deferred Tax Long-Term Investments Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Prepaid Assets Property, Plant & Equipment (Net)Raw Materials Receivables Retained Earnings Shareholder's Equity Shares Outstanding Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Work In Process

Daily Values

Growth Metrics

Others

Immucell (ICCC) Construction in Progress (2016 - 2024)

Immucell's Construction in Progress history spans 7 years, with the latest figure at $2.3 million for Q4 2024.

For Q4 2024, Construction in Progress changed N/A year-over-year to $2.3 million; the TTM value through Dec 2024 reached $2.3 million, changed N/A, while the annual FY2024 figure was $2.3 million, N/A changed from the prior year.
Construction in Progress reached $2.3 million in Q4 2024 per ICCC's latest filing, down from $17.1 million in the prior quarter.
In the past five years, Construction in Progress ranged from a high of $2.3 million in Q4 2024 to a low of $2.3 million in Q4 2024.